Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.
November 03, 2021
Share
Beijing Konruns Pharmaceutical Co.,Ltd. (SHSE:603590) intends to acquire 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited for approximately CNY 130 million on October 12, 2021. The consideration will be paid in cash. Prior to transaction, Beijing Konruns Pharmaceutical Co.,Ltd. holds 60% stake and NT Pharma Pacific Company Limited holds 40% stake in Beijing Konruns Biotechnology Co., Ltd. Post completion, Beijing Konruns Pharmaceutical Co.,Ltd. holds 73.7% stake and NT Pharma Pacific Company Limited holds 26.3% stake in Beijing Konruns Biotechnology Co., Ltd. The transaction has been unanimously reviewed and approved at the 21st meeting of the third board of directors held on October 11, 2021. As of December 31, 2020, Beijing Konruns Biotechnology Co., Ltd. had total assets of CNY 1.3 billion and net assets of CNY 835 million. For the year ending December 31, 2020, Beijing Konruns Biotechnology Co., Ltd. reported EBIT of CNY 19.1 million and net loss of CNY 20 million.
Beijing Konruns Pharmaceutical Co.,Ltd. (SHSE:603590) completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited on November 4, 2021.
Beijing Konruns Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of drugs. The Company's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Companyâs present products under research include a range of innovative and generic drugs for tumors and blood. The Company mainly distributes its products in the domestic market.
Beijing Konruns Pharmaceutical Co.,Ltd. completed the acquisition of 13.70% stake in Beijing Konruns Biotechnology Co., Ltd. from NT Pharma Pacific Company Limited.